German life sciences company Merck KGaA (MRK: DE) today announced that the Phase III MANEUVER trial of pimicotinib met its ...

while in life science, it seeks to support biopharmaceutical companies in China with breakthrough technologies in areas like ...

Cepheid congratulates Executive Vice President, Chief Medical and Scientific Officer, David H. Persing, MD, Ph.D., for receiving the 2024 California Life Sciences (CLS) Pantheon Leadership award. The ...

Novel MEK blocker shows promise in rare genetic disorder ...

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs ...

Vietnam Expands for 2025 with Addition of New Hall - The largest edition yet, nearly double the size of the 2023 edition. - ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

The Mectizan Donation Program applauds Timor-Leste for eliminating lymphatic filariasis (LF) as a public health problem, a ...